Sjögren's syndrome overview: Difference between revisions
Farima Kahe (talk | contribs) |
Farima Kahe (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
' | In 1892, Johann von Mikulicz-Radecki was to first to describe a patient with with enlargement of the [[parotid]] and [[lacrimal glands]] associated with a round-cell infiltrate and [[acinar]] [[atrophy]]. In 1933, Henrik Sjögren was the first to describe 19 females with clinical and pathological manifestations of the Sjögren's syndrome. American-European Consensus Group(AECG) and American College of Rheumatology (ACR) established the criteria for Sjögren’s syndrome in 2002 and 2012 according to [[clinical]] findings. Common causes of Sjögren's syndrome include viral infection such as [[Epstein Barr virus|Epstein-Barr virus]] (EBV), [[Coxsackie virus]], [[Hepatitis C virus]], [[Cytomegalovirus]] (CMV), [[Human herpesvirus 6]] (HHV-6), [[Retroviruses]] and [[genetic]] factors. The [[incidence]] of Sjögren's syndrome is approximately 4 per 100,000 individuals worldwide. The [[prevalence]] of Sjögren's syndrome is approximately 43 per 100,000 individuals worldwide. Female are more commonly affected by Sjögren's syndrome than male. The majority of Sjögren's syndrome cases are reported in China, Japan, and California. Common risk factors in the development of Sjögren's syndrome include family history of [[autoimmune diseases]], serological markers such as low complement levels and [[cryoglobulinaemia]] and [[parotid gland enlargement]]. The symptoms of Sjögren's syndrome usually develop in the 4th and 5th decade of life, and start with symptoms such as [[ocular]] and [[oral]] dryness. Common complications of Sjögren's syndrome include [[blurred vision]] and [[corneal]] damage, [[optic neuritis]] and lymphoma. [[Prognosis]] is generally good and presence of low [[complement]] level is associated with a particularly poor [[prognosis]] among patients with Sjögren's syndrome. The most common symptoms of Sjögren's syndrome include ocular and oral symptoms. Patients with Sjögren's syndrome may have a positive history of [[rheumatoid arthritis]] (RA), [[systemic lupus erythematous]] (SLE) and non-Hodgkin B-cell lymphoma. Physical examination of patients with is usually remarkable for dryness of all [[mucous membranes]] such as mouth, eyes, lips, [[anal]] and [[rectal]]. Laboratory findings consistent with the diagnosis of Sjögren's syndrome include [[erythrocyte sedimentation rate|Elevated erythrocyte sedimentation rate]] (ESR), [[cytopenia]], presence of anti-SSA/Ro, anti-SSB/La. Findings on an [[ultrasound]] suggestive of Sjögren's syndrome are hypoechoic and inhomogeneous [[salivary glands]], [[parenchymal]] inhomogeneity in the [[submandibular]] glands and focal or diffuse hypoechoic or anechoic foci in glands. Parotid gland CT scan may be helpful in the diagnosis of Sjögren's syndrome and finding include abnormal [[diffuse]] fat tissue deposition and diffuse punctate [[calcification]]. The most commonly used tests for dry eyes of Sjögren's syndrome include Schirmer test, ocular surface staining and tear break-up time. Pharmacologic medical therapies for dry eye, dry mouth, and other sicca symptom of Sjögren's syndrome are [[Pilocarpine]], [[Cevimeline]] and artifical tears. The mainstay of treatment for Sjögren's syndrome is medical therapy. Surgery is usually reserved for patients with [[occlusion]] of the lacrimal puncta, [[salivary gland]] [[malignancy]] and recurrent [[parotitis]] refractory to medical management. | ||
==Historical Perspective== | ==Historical Perspective== | ||
| Line 58: | Line 56: | ||
==Treatment== | ==Treatment== | ||
===Medical Therapy=== | ===Medical Therapy=== | ||
Pharmacologic medical therapies for dry eye, dry mouth, and other sicca symptom of Sjögren's syndrome are [[Pilocarpine]], [[Cevimeline]] and artifical tears. | |||
===Surgery=== | ===Surgery=== | ||
The mainstay of treatment for Sjögren's syndrome is medical therapy. Surgery is usually reserved for patients with [[occlusion]] of the lacrimal puncta, [[salivary gland]] [[malignancy]] and recurrent [[parotitis]] refractory to medical management. | |||
===Prevention=== | ===Prevention=== | ||
Revision as of 17:04, 10 April 2018
|
Sjögren's syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Sjögren's syndrome overview On the Web |
|
American Roentgen Ray Society Images of Sjögren's syndrome overview |
|
Risk calculators and risk factors for Sjögren's syndrome overview |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
In 1892, Johann von Mikulicz-Radecki was to first to describe a patient with with enlargement of the parotid and lacrimal glands associated with a round-cell infiltrate and acinar atrophy. In 1933, Henrik Sjögren was the first to describe 19 females with clinical and pathological manifestations of the Sjögren's syndrome. American-European Consensus Group(AECG) and American College of Rheumatology (ACR) established the criteria for Sjögren’s syndrome in 2002 and 2012 according to clinical findings. Common causes of Sjögren's syndrome include viral infection such as Epstein-Barr virus (EBV), Coxsackie virus, Hepatitis C virus, Cytomegalovirus (CMV), Human herpesvirus 6 (HHV-6), Retroviruses and genetic factors. The incidence of Sjögren's syndrome is approximately 4 per 100,000 individuals worldwide. The prevalence of Sjögren's syndrome is approximately 43 per 100,000 individuals worldwide. Female are more commonly affected by Sjögren's syndrome than male. The majority of Sjögren's syndrome cases are reported in China, Japan, and California. Common risk factors in the development of Sjögren's syndrome include family history of autoimmune diseases, serological markers such as low complement levels and cryoglobulinaemia and parotid gland enlargement. The symptoms of Sjögren's syndrome usually develop in the 4th and 5th decade of life, and start with symptoms such as ocular and oral dryness. Common complications of Sjögren's syndrome include blurred vision and corneal damage, optic neuritis and lymphoma. Prognosis is generally good and presence of low complement level is associated with a particularly poor prognosis among patients with Sjögren's syndrome. The most common symptoms of Sjögren's syndrome include ocular and oral symptoms. Patients with Sjögren's syndrome may have a positive history of rheumatoid arthritis (RA), systemic lupus erythematous (SLE) and non-Hodgkin B-cell lymphoma. Physical examination of patients with is usually remarkable for dryness of all mucous membranes such as mouth, eyes, lips, anal and rectal. Laboratory findings consistent with the diagnosis of Sjögren's syndrome include Elevated erythrocyte sedimentation rate (ESR), cytopenia, presence of anti-SSA/Ro, anti-SSB/La. Findings on an ultrasound suggestive of Sjögren's syndrome are hypoechoic and inhomogeneous salivary glands, parenchymal inhomogeneity in the submandibular glands and focal or diffuse hypoechoic or anechoic foci in glands. Parotid gland CT scan may be helpful in the diagnosis of Sjögren's syndrome and finding include abnormal diffuse fat tissue deposition and diffuse punctate calcification. The most commonly used tests for dry eyes of Sjögren's syndrome include Schirmer test, ocular surface staining and tear break-up time. Pharmacologic medical therapies for dry eye, dry mouth, and other sicca symptom of Sjögren's syndrome are Pilocarpine, Cevimeline and artifical tears. The mainstay of treatment for Sjögren's syndrome is medical therapy. Surgery is usually reserved for patients with occlusion of the lacrimal puncta, salivary gland malignancy and recurrent parotitis refractory to medical management.
Historical Perspective
In 1892, Johann von Mikulicz-Radecki was to first to describe a patient with with enlargement of the parotid and lacrimal glands associated with a round-cell infiltrate and acinar atrophy. In 1933, Henrik Sjögren was the first to describe 19 females with clinical and pathological manifestations of the Sjögren's syndrome.
Classification
American-European Consensus Group(AECG) and American College of Rheumatology (ACR) established the criteria for Sjögren’s syndrome in 2002 and 2012 according to clinical findings.
Pathophysiology
Causes
Common causes of Sjögren's syndrome include viral infection such as Epstein-Barr virus (EBV), Coxsackie virus, Hepatitis C virus, Cytomegalovirus (CMV), Human herpesvirus 6 (HHV-6), Retroviruses and genetic factors.
Differentiating Sjögren's syndrome overview from Other Diseases
Epidemiology and Demographics
The incidence of Sjögren's syndrome is approximately 4 per 100,000 individuals worldwide. The prevalence of Sjögren's syndrome is approximately 43 per 100,000 individuals worldwide. Female are more commonly affected by Sjögren's syndrome than male. The majority of Sjögren's syndrome cases are reported in China, Japan, and California.
Risk Factors
Common risk factors in the development of Sjögren's syndrome include family history of autoimmune diseases, serological markers such as low complement levels and cryoglobulinaemia and parotid gland enlargement.
Screening
There is insufficient evidence to recommend routine screening for Sjögren's syndrome.
Natural History, Complications, and Prognosis
Natural History
The symptoms of Sjögren's syndrome usually develop in the 4th and 5th decade of life, and start with symptoms such as ocular and oral dryness.
Complications
Common complications of Sjögren's syndrome include blurred vision and corneal damage, optic neuritis and lymphoma.
Prognosis
Prognosis is generally good and presence of low complement level is associated with a particularly poor prognosis among patients with Sjögren's syndrome.
Diagnosis
Diagnostic Criteria
History and Symptoms
The most common symptoms of Sjögren's syndrome include ocular and oral symptoms. Patients with Sjögren's syndrome may have a positive history of rheumatoid arthritis (RA), systemic lupus erythematous (SLE) and non-Hodgkin B-cell lymphoma.
Physical Examination
Physical examination of patients with is usually remarkable for dryness of all mucous membranes such as mouth, eyes, lips, anal and rectal.
Laboratory Findings
Laboratory findings consistent with the diagnosis of Sjögren's syndrome include Elevated erythrocyte sedimentation rate (ESR), cytopenia, presence of anti-SSA/Ro, anti-SSB/La.
Imaging Findings
Findings on an ultrasound suggestive of Sjögren's syndrome are hypoechoic and inhomogeneous salivary glands, parenchymal inhomogeneity in the submandibular glands and focal or diffuse hypoechoic or anechoic foci in glands. Parotid gland CT scan may be helpful in the diagnosis of Sjögren's syndrome and finding include abnormal diffuse fat tissue deposition and diffuse punctate calcification.
Other Diagnostic Studies
The most commonly used tests for dry eyes of Sjögren's syndrome include Schirmer test, ocular surface staining and tear break-up time.
Treatment
Medical Therapy
Pharmacologic medical therapies for dry eye, dry mouth, and other sicca symptom of Sjögren's syndrome are Pilocarpine, Cevimeline and artifical tears.
Surgery
The mainstay of treatment for Sjögren's syndrome is medical therapy. Surgery is usually reserved for patients with occlusion of the lacrimal puncta, salivary gland malignancy and recurrent parotitis refractory to medical management.